Please Wait.....
Report
Global Cell Therapy Manufacturing Market Report and Forecast 2023-2031
Market Report I 2023-06-14 I 140 Pages I EMR Inc.
Global Cell Therapy Manufacturing Market Report and Forecast 2023-2031
Global Cell Therapy Manufacturing Market Outlook
The global cell therapy manufacturing market size was valued at USD 3.7 billion in 2022, driven by the increasing technological advancement in the cell therapies across the globe. The market size is anticipated to grow at a CAGR of 14.71% during the forecast period of 2023-2031 to achieve a value of USD 12.8 billion by 2031.
Cell Therapy Manufacturing: Introduction
Cell therapy is a rapidly evolving field in medicine that involves the use of living cells to treat various diseases and medical conditions. It holds great promise for regenerative medicine, immunotherapy, and other therapeutic applications. Cell therapy manufacturing refers to the process of manufacturing and producing these specialized cell-based therapies in a controlled and scalable manner.
Key Trends in the Global Cell Therapy Manufacturing Market
There are several key trends in the market and some of them are:
- Advanced Manufacturing Technologies: One of the key trends in cell therapy manufacturing is the development and adoption of advanced manufacturing technologies. This includes the use of automated systems, robotics, and closed-system manufacturing platforms to enhance the efficiency, reproducibility, and quality control of cell therapy production. Advanced manufacturing technologies help to streamline processes, reduce costs, and increase the scalability of cell therapy manufacturing.
- Standardization and Quality Assurance: With the increasing number of cell therapy products in development and clinical use, there is a growing focus on standardization and quality assurance in cell therapy manufacturing. Standardized protocols and manufacturing processes are being established to ensure consistent product quality, safety, and efficacy. Regulatory agencies are also providing guidelines and regulations to ensure compliance with good manufacturing practices (GMP) and quality control standards.
- Scale-Up and Commercialization: As cell therapies move from the research and development phase to commercialization, there is a need for scalable manufacturing processes to meet the increasing demand. Key trends in cell therapy manufacturing include the development of large-scale bioreactors, expansion technologies, and scalable manufacturing platforms to enable the efficient production of cell therapies at a commercial scale. This involves addressing challenges such as cell expansion, cell viability, and maintaining product consistency during scale-up.
- Supply Chain and Logistics: The supply chain and logistics involved in cell therapy manufacturing are critical for ensuring the timely and safe delivery of cell therapies to patients. Key trends in this area include the development of specialized storage and transportation solutions, cryopreservation technologies, and cold chain management systems. These advancements help to maintain the viability and functionality of the cells during storage and transportation, ensuring their therapeutic efficacy upon administration.
- Process Optimization and Cost Reduction: As cell therapy manufacturing becomes more widespread, there is a focus on process optimization and cost reduction. Manufacturers are continuously improving the efficiency of manufacturing processes, implementing process analytical technologies (PAT), and adopting innovative approaches to reduce production costs while maintaining product quality. This includes the development of more efficient cell culture media, bioprocess optimization strategies, and cost-effective manufacturing platforms.
Global Cell Therapy Manufacturing Market Segmentations
Market Breakup by Therapy Type
- T-Cell Therapies
- Dendritic Cell Therapies
- Tumor Cell Therapies
- Stem Cell Therapies
- Others
Market Breakup by Technology
- Somatic Cell Technology
- Cell Immortalization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
- Others
Market Breakup by Source of Cell
- Autologous Cell
- Allogeneic Cell
Market Breakup by Scale of Operation
- Preclinical
- Clinical
- Commercial
Market Breakup by Applications
- Oncology
- Cardiovascular Diseases
- Orthopedic Diseases
- Others
Market Breakup by End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cell Therapy Manufacturing Market Scenario
The cell therapy manufacturing market is a rapidly growing sector within the healthcare industry. It involves the production of therapeutic cells that are used in the treatment of various diseases and conditions. Cell therapies offer promising solutions for diseases that have limited treatment options, such as cancer, autoimmune disorders, and genetic disorders.
The market for cell therapy manufacturing is driven by several factors. First and foremost, there is a growing demand for innovative and personalized therapies that can provide better treatment outcomes and improve patient quality of life. Cell therapies have shown remarkable efficacy in certain indications and have gained attention from healthcare providers, patients, and investors.
Another factor driving market growth is the advancements in cell therapy manufacturing technologies. This includes the development of closed-system manufacturing platforms, automation, and scalable bioreactors. These technologies enable efficient and cost-effective production of cell therapies, addressing the challenges of scalability and consistency in manufacturing.
Overall, the cell therapy manufacturing market presents significant opportunities for companies involved in cell therapy research, development, and manufacturing. As more cell therapies enter clinical trials and gain regulatory approvals, the market is expected to experience substantial growth in the coming years. However, challenges such as high treatment costs, reimbursement issues, and complex manufacturing processes need to be addressed for the market to reach its full potential.
Global Cell Therapy Manufacturing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- F.Hoffmann La Roche AG
- Gilead Sciences, Inc.
- Thermo Fischer Scientific, Inc.
- Catalent, Inc.
- JSR Life Sciences LLC (KBI Biopharma Inc)
- Waisman Center (Waisman Biomanufacturing)
- Cell and Gene Therapy Catapult
- Merck KGaA
- Lonza Group
- Oxford Biomedica Plc
- WuXi AppTec
- Charles River Laboratories International Inc.
- Institut Merieux (ABL Inc.)
- BioCentriq
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
- Amgen Inc.
- Bluebird Bio Inc.
- Takeda Pharmaceutical Company Limited
*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell Therapy Manufacturing Market Overview
3.1 Global Cell Therapy Manufacturing Market Historical Value (2016-2022)
3.2 Global Cell Therapy Manufacturing Market Forecast Value (2023-2031)
4 Global Cell Therapy Manufacturing Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter's Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Cell Therapy Manufacturing Market Segmentation
5.1 Global Cell Therapy Manufacturing Market by Therapy Type
5.1.1 Market Overview
5.1.2 T-Cell Therapies
5.1.3 Dendritic Cell Therapies
5.1.4 Tumour Cell Therapies
5.1.5 Stem Cell Therapies
5.1.6 Others
5.2 Global Cell Therapy Manufacturing Market by Technology
5.2.1 Market Overview
5.2.2 Somatic Cell Technology
5.2.3 Cell Immortalization Technology
5.2.4 Viral Vector Technology
5.2.5 Genome Editing Technology
5.2.6 Cell Plasticity Technology
5.2.7 3D Technology
5.2.8 Others
5.3 Global Cell Therapy Manufacturing Market by Source of Cell
5.3.1 Market Overview
5.3.2 Autologous Cell
5.3.3 Allogeneic Cell
5.4 Global Cell Therapy Manufacturing Market by Scale of Operation
5.4.1 Market Overview
5.4.2 Preclinical
5.4.3 Clinical
5.4.4 Commercial
5.5 Global Cell Therapy Manufacturing Market by Applications
5.5.1 Market Overview
5.5.2 Oncology
5.5.3 Cardiovascular Diseases
5.5.4 Orthopaedic Diseases
5.5.5 Others
5.6 Global Cell Therapy Manufacturing Market by End User
5.6.1 Market Overview
5.6.2 Pharmaceutical and Biotechnology Companies
5.6.3 Academic and Research Institutes
5.6.4 Others
5.7 Global Cell Therapy Manufacturing Market by Region
5.7.1 Market Overview
5.7.2 North America
5.7.3 Europe
5.7.4 Asia Pacific
5.7.5 Latin America
5.7.6 Middle East and Africa
6 North America Cell Therapy Manufacturing Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Cell Therapy Manufacturing Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Cell Therapy Manufacturing Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.5 ASEAN
8.6 Australia
8.7 Others
9 Latin America Cell Therapy Manufacturing Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Cell Therapy Manufacturing Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Supplier Landscape
16.1 Novartis AG
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.1.5 Certifications
16.2 F.Hoffmann La Roche AG
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Gilead Sciences, Inc.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Thermo Fischer Scientific, Inc.
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Catalent, Inc.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 JSR Life Sciences LLC (KBI Biopharma Inc)
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Waisman Center (Waisman Biomanufacturing)
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Cell and Gene Therapy Catapult
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Merck KGaA
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Lonza Group
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Oxford Biomedica Plc
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
16.12 WuXi AppTec
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.12.5 Certifications
16.13 Charles River Laboratories International Inc.
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisitions
16.13.5 Certifications
16.14 Institut Merieux (ABL Inc.)
16.14.1 Financial Analysis
16.14.2 Product Portfolio
16.14.3 Demographic Reach and Achievements
16.14.4 Mergers and Acquisitions
16.14.5 Certifications
16.15 BioCentriq
16.15.1 Financial Analysis
16.15.2 Product Portfolio
16.15.3 Demographic Reach and Achievements
16.15.4 Mergers and Acquisitions
16.15.5 Certifications
16.16 Centre for Commercialization of Regenerative Medicine (CCRM)
16.16.1 Financial Analysis
16.16.2 Product Portfolio
16.16.3 Demographic Reach and Achievements
16.16.4 Mergers and Acquisitions
16.16.5 Certifications
16.17 Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
16.17.1 Financial Analysis
16.17.2 Product Portfolio
16.17.3 Demographic Reach and Achievements
16.17.4 Mergers and Acquisitions
16.17.5 Certifications
16.18 Amgen Inc.
16.18.1 Financial Analysis
16.18.2 Product Portfolio
16.18.3 Demographic Reach and Achievements
16.18.4 Mergers and Acquisitions
16.18.5 Certifications
16.19 Bluebird Bio Inc.
16.19.1 Financial Analysis
16.19.2 Product Portfolio
16.19.3 Demographic Reach and Achievements
16.19.4 Mergers and Acquisitions
16.19.5 Certifications
16.20 Takeda Pharmaceutical Company Limited
16.20.1 Financial Analysis
16.20.2 Product Portfolio
16.20.3 Demographic Reach and Achievements
16.20.4 Mergers and Acquisitions
16.20.5 Certifications
17 Global Cell Therapy Manufacturing Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security